New injection aims to curb bleeding in rare clotting disorder
NCT ID NCT07711158
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This phase II trial tests an injected drug called SR604 in people with congenital Factor VII deficiency, a rare bleeding disorder. The goal is to see if SR604 can reduce the number of bleeding episodes and improve safety. The study includes 12 participants aged 12 to 65 who have had at least two treated bleeds in the past three months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SR604 injection
- What this could lead to
- If successful, SR604 could offer a new way to prevent bleeding episodes in people with Factor VII deficiency, reducing the need for frequent infusions.
- What could go wrong
- This is a small, early-phase trial with only 12 participants, so results may not apply to everyone. The drug may not effectively reduce bleeding or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL COAGULATION FACTOR VII DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.